These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 2454576

  • 1. Evaluation of TSH-receptor antibodies as prognostic markers after cessation of antithyroid drug treatment in patients with Graves' disease.
    Kasagi K, Iida Y, Hatabu H, Tokuda Y, Arai K, Endo K, Konishi J.
    Acta Endocrinol (Copenh); 1988 Feb; 117(2):173-80. PubMed ID: 2454576
    [Abstract] [Full Text] [Related]

  • 2. Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay.
    Maugendre D, Massart C.
    Clin Endocrinol (Oxf); 2001 Jan; 54(1):89-96. PubMed ID: 11167931
    [Abstract] [Full Text] [Related]

  • 3. Thyroid-stimulating antibody and TSH-binding inhibitor immunoglobulin in 277 Graves' patients and in 686 normal subjects.
    Takasu N, Oshiro C, Akamine H, Komiya I, Nagata A, Sato Y, Yoshimura H, Ito K.
    J Endocrinol Invest; 1997 Sep; 20(8):452-61. PubMed ID: 9364248
    [Abstract] [Full Text] [Related]

  • 4. [Clinical studies on abnormal thyroid stimulators in patients with Graves' disease. II. Clinical significance of measuring TSAb and TBII in patients with euthyroid Graves' disease and patients with hyperthyroid Graves' disease during antithyroid drug treatment].
    Uno C, Nishikawa M.
    Nihon Naibunpi Gakkai Zasshi; 1988 Mar 20; 64(3):206-15. PubMed ID: 2456230
    [Abstract] [Full Text] [Related]

  • 5. Remission of Graves' hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment.
    Takasu N, Yamashiro K, Komiya I, Ochi Y, Sato Y, Nagata A.
    Thyroid; 2000 Oct 20; 10(10):891-6. PubMed ID: 11081255
    [Abstract] [Full Text] [Related]

  • 6. Studies on thyrotrophin receptor antibodies in patients with euthyroid Graves' disease.
    Kasagi K, Hatabu H, Tokuda Y, Iida Y, Endo K, Konishi J.
    Clin Endocrinol (Oxf); 1988 Oct 20; 29(4):357-66. PubMed ID: 2908031
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of serum basal thyrotrophin levels and thyrotrophin receptor antibody activities as prognostic markers for discontinuation of antithyroid drug treatment in patients with Graves' disease.
    Cho BY, Shong MH, Yi KH, Lee HK, Koh CS, Min HK.
    Clin Endocrinol (Oxf); 1992 Jun 20; 36(6):585-90. PubMed ID: 1358483
    [Abstract] [Full Text] [Related]

  • 8. The relationships between serum T3 index, thyroid volume, and thyroid stimulating, TSH receptor binding and thyroid growth stimulating antibodies in untreated Graves' disease.
    Bliddal H, Hegedüs L, Hansen JM, Bech K, van der Gaag R, Drexhage HA.
    Clin Endocrinol (Oxf); 1987 Jul 20; 27(1):75-84. PubMed ID: 2888551
    [Abstract] [Full Text] [Related]

  • 9. [The prognosis of Graves' disease after antithyroid drug treatment: clinical significance of the T3 suppression test and abnormal thyroid stimulators].
    Iida Y, Konishi J, Kasagi K, Misaki T, Endo K, Nesumi N, Torizuka K, Tanaka K, Ishii H, Naito K, Nishikawa M, Inada M, Imura H, Kuma K.
    Nihon Naibunpi Gakkai Zasshi; 1982 Jun 20; 58(6):796-806. PubMed ID: 6180937
    [Abstract] [Full Text] [Related]

  • 10. A study of untreated Graves' patients with undetectable TSH binding inhibitor immunoglobulins and the effect of anti-thyroid drugs.
    Kawai K, Tamai H, Matsubayashi S, Mukuta T, Morita T, Kubo C, Kuma K.
    Clin Endocrinol (Oxf); 1995 Nov 20; 43(5):551-6. PubMed ID: 8548939
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Assays for thyroid-stimulating antibodies and thyrotropin-binding inhibitory immunoglobulins in children with Graves' disease.
    Shibayama K, Ohyama Y, Yokota Y, Ohtsu S, Takubo N, Matsuura N.
    Endocr J; 2005 Oct 20; 52(5):505-10. PubMed ID: 16284425
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Prognostic value of thyroid stimulating antibodies and TSH-binding inhibiting immunoglobulins in the follow-up of Graves' disease.
    Hörmann R, Saller B, Müller R, Mann K.
    Klin Wochenschr; 1985 Dec 16; 63(24):1247-52. PubMed ID: 2868149
    [Abstract] [Full Text] [Related]

  • 17. Immunoglobulins of untreated Graves' patients with or without thyrotropin receptor antibody (determined by porcine thyrocytes) universally elicit potent thyroid hormone-releasing activity in cultured human thyroid follicles.
    Sato K, Yamazaki K, Yamada E, Kanaji Y, Miura M, Obara T.
    Thyroid; 1999 Oct 16; 9(10):979-88. PubMed ID: 10560951
    [Abstract] [Full Text] [Related]

  • 18. Paired determination of thyroid-stimulating and TSH-binding inhibitory activities in patients with Graves' disease during antithyroid drug treatment.
    Kasagi K, Iida Y, Konishi J, Misaki T, Arai K, Endo K, Torizuka K, Kuma K.
    Acta Endocrinol (Copenh); 1986 Apr 16; 111(4):474-80. PubMed ID: 2422860
    [Abstract] [Full Text] [Related]

  • 19. Practical treatment with minimum maintenance dose of anti-thyroid drugs for prediction of remission in Graves' disease.
    Kashiwai T, Hidaka Y, Takano T, Tatsumi KI, Izumi Y, Shimaoka Y, Tada H, Takeoka K, Amino N.
    Endocr J; 2003 Feb 16; 50(1):45-9. PubMed ID: 12733708
    [Abstract] [Full Text] [Related]

  • 20. Clinical validity of a new commercial method for detection of TSH-receptor binding antibodies in sera from patients with Graves' disease treated with antithyroid drugs.
    Massart C, Orgiazzi J, Maugendre D.
    Clin Chim Acta; 2001 Feb 16; 304(1-2):39-47. PubMed ID: 11165197
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.